Analysts Offer Insights on Healthcare Companies: uniQure NV (NASDAQ: QURE) and Emergent Biosolutions (NYSE: EBS)

By Carrie Williams

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on uniQure NV (QUREResearch Report) and Emergent Biosolutions (EBSResearch Report).

uniQure NV (QURE)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on uniQure NV, with a price target of $175. The company’s shares closed last Monday at $54.25.

Amusa observed:

“We continue our bullish QURE thesis (and affirm our $175 price target) ahead of what we see as among the most compelling 2020 catalysts in biotech:.”

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 18.1% and a 49.4% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catalyst Biosciences Inc, and Voyager Therapeutics Inc.

uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $99.40.

See today’s analyst top recommended stocks >>

Emergent Biosolutions (EBS)

In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Emergent Biosolutions, with a price target of $60. The company’s shares closed last Monday at $43.80, close to its 52-week low of $39.11.

According to TipRanks.com, Peaker is a 1-star analyst with an average return of -0.2% and a 40.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $65.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.